{"id":27486,"date":"2025-04-17T12:15:09","date_gmt":"2025-04-17T12:15:09","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/27486\/"},"modified":"2025-04-17T12:15:09","modified_gmt":"2025-04-17T12:15:09","slug":"il-5-inhibitors-may-be-steroid-alternative-for-rx-of-dress","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/27486\/","title":{"rendered":"IL-5 Inhibitors May Be Steroid Alternative For Rx of DRESS"},"content":{"rendered":"<p><strong>TOPLINE:<\/strong><\/p>\n<p>A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved clinical outcomes in patients with drug reaction with eosinophilia and systemic symptoms (DRESS), with no adverse events or long-term autoimmune sequelae.<\/p>\n<p><strong>METHODOLOGY:<\/strong><\/p>\n<ul>\n<li>Researchers conducted a retrospective case series of 16 patients treated with IL-5 inhibitors across the Mass General Brigham system, of whom five (two women, five men) met criteria for possible DRESS (Registry of Severe Cutaneous Adverse Reactions score \u2265 3).<\/li>\n<li>The mean peak absolute eosinophil count was 5200 (range, 1800-10,000) cells\/\u03bcL.<\/li>\n<li>The patients required IL-5 inhibitors (mepolizumab or benralizumab) because of contraindications to or failure of oral, intravenous, or ocular steroid treatment or various immunomodulators.<\/li>\n<li>Clinical response was defined as resolution of cutaneous symptoms and sustained recovery of organ involvement.<\/li>\n<\/ul>\n<p><strong>TAKEAWAY:<\/strong><\/p>\n<ul>\n<li>Researchers reported a dramatic reduction in eosinophilia within 1-3 days for all patients, with a mean time to eosinophil resolution of 1.4 days.<\/li>\n<li>The mean time to clinical response was 16 days, sustained resolution observed in follow-up periods ranging from 57 to 793 days.<\/li>\n<li>One patient relapsed after 13 days on mepolizumab but responded well to benralizumab, achieving a sustained reduction in eosinophil levels.<\/li>\n<li>No adverse events or long-term autoimmune sequelae were reported.<\/li>\n<\/ul>\n<p><strong>IN PRACTICE:<\/strong><\/p>\n<p>\u201cOur work highlights a potentially safe and effective alternative to mainline steroid-sparing immunomodulators in reducing eosinophil levels and providing sustained clinical relief\u201d for DRESS, the authors wrote; they called for larger prospective studies to validate the findings.<\/p>\n<p><strong>SOURCE:<\/strong><\/p>\n<p>The study was led by Baraa Hijaz, Harvard Medical School, Boston. It was <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/10.1001\/jamadermatol.2025.0441\" target=\"_blank\" rel=\"noopener\">published online<\/a> on April 16 in JAMA Dermatology.<\/p>\n<p><strong>LIMITATIONS:<\/strong><\/p>\n<p>Study limitations included the retrospective design and a small sample size. Short follow-up was reported in two patients.<\/p>\n<p><strong>DISCLOSURES:<\/strong><\/p>\n<p>The authors did not disclose any funding source. One author reported receiving royalties from McGraw Hill outside the submitted work.<\/p>\n<p>This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/p>\n","protected":false},"excerpt":{"rendered":"TOPLINE: A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved&hellip;\n","protected":false},"author":2,"featured_media":27487,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[16590,16591,16601,16596,16593,16595,16592,105,16597,16599,16598,4326,16600,16602,16594,16,15],"class_list":{"0":"post-27486","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-biologic-therapy","9":"tag-biologics","10":"tag-cetuximab","11":"tag-drug-reaction","12":"tag-eosinophil-granulocytes","13":"tag-eosinophilia","14":"tag-eosinophils","15":"tag-health","16":"tag-immunomodulator","17":"tag-interleukins","18":"tag-lenalidomide","19":"tag-medication","20":"tag-monoclonal-antibody","21":"tag-rituximab","22":"tag-steroids","23":"tag-uk","24":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114353256726265668","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/27486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=27486"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/27486\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/27487"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=27486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=27486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=27486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}